Indivior's SUBLOCADE Data Reinforces Clinical Benefits, Supports Remission in OUD Treatment
INDV has more than doubled off its 52-week low of $10.21 on light trading volume (0.1× avg).
Summary
Indivior presented new real-world data at the ASAM 2026 Annual Conference, reinforcing the clinical benefits of its monthly injectable buprenorphine, SUBLOCADE®, for Opioid Use Disorder (OUD). The data supports remission as a key treatment outcome and indicates reduced overdose risk. This follows recent news from April 16th regarding a survey on long-acting injectables, demonstrating Indivior's ongoing efforts to expand the evidence base for its OUD treatments. This positive data strengthens SUBLOCADE's market position and could support increased adoption, which is material for a key product in the company's core business. Investors should monitor future sales trends and further data presentations.
At the time of this announcement, INDV was trading at $32.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $10.21 to $38.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.